Tuesday 4 September 2012

Pfizer kidney cancer drug gets EU approval

(Reuters) - Pfizer Inc said its oral drug Inlyta received European approval as a second-line treatment for kidney cancer patients who do not respond to an initial chemotherapy. The company said the approval was based on data from a late-stage trial which showed that the drug significantly extended progression-free survival in patients who failed to respond to treatment with Pfizer's Sutent. Inlyta was approved in the United States for the same indication in January. The drug, generically known as axitinib, works by inhibiting proteins that can influence tumor growth and cancer progression. ... via Health News Headlines - Yahoo! News Read More Here..

No comments:

Post a Comment